Stay updated with breaking news from Active Ingredient. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "MHealth Market Size, Share & Trends Analysis Report By...
A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.
A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.
Ozempic, the uber-popular injectable diabetes drug, has had to update its potential side effect warnings to include intestinal blockage. As CBS News reports, the Ozempic label change reflects updates posted last week by the Food and Drug Administration which acknowledged that some users experienced a condition known as "ileus," which involves a blocking of the intestines. […]
/PRNewswire/ -- According to a comprehensive research report by Brandessence Market Research (BMRC), "Wearable Medical Devices Market By Product Type, By...